Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Enapotamab vedotin (HuMax-AXL-ADC)
Enapotamab vedotin · 1 trial · 8 indications
| Name | Type | Description |
|---|---|---|
| Enapotamab vedotin (HuMax-AXL-ADC) | BIOLOGICAL | Enapotamab vedotin (HuMax-AXL-ADC) will be administered intravenously. |
Top 20 of 60 competitors
Enapotamab vedotin is an investigational antibody-drug conjugate developed by Genmab A/S for the treatment of solid tumors, including ovarian cancer. It is designed to deliver a cytotoxic payload to tumor cells. It has been studied in a Phase 1/Phase 2 clinical trial and is not approved for commercial use.
Enapotamab vedotin has been studied in ovarian cancer as part of a Phase 1/Phase 2 trial in patients with solid tumors. The study also enrolled patients with cervical cancer, endometrial cancer, non-small cell lung cancer, thyroid cancer, melanoma, and sarcoma. It remains an investigational agent and is not approved for ovarian cancer treatment.
Enapotamab vedotin targets AXL, a receptor tyrosine kinase, and also binds tubulin proteins including TUBB4B, TUBB1, TUBA3C, TUBA4A, and TUBB3. As an antibody-drug conjugate, it combines an AXL-directed antibody with a microtubule-disrupting payload to deliver cytotoxicity to AXL-expressing tumor cells.
Enapotamab vedotin is developed by Genmab A/S, a Danish biotechnology company listed under the ticker GMAB. Genmab conducted the clinical development of the agent, including the Phase 1/Phase 2 safety study in patients with solid tumors.
Enapotamab vedotin reached Phase 2 development. It was evaluated in a Phase 1/Phase 2 clinical trial, and that study has been completed. The drug is investigational and has not been approved by the FDA for any indication.
Enapotamab vedotin was studied in clinical trial NCT02988817, titled "Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors." This Phase 1/Phase 2 trial enrolled 306 patients across multiple solid tumor types and has been completed. No active trials are currently listed for this agent.
Yes, enapotamab vedotin is also known as HuMax-AXL-ADC. HuMax-AXL-ADC was the earlier research name used for the same antibody-drug conjugate developed by Genmab A/S. Both names refer to the same investigational agent studied in solid tumors, including ovarian cancer.